Nantong Materia Medica Bada Pharmaceutical Technology

Nantong Materia Medica Bada Pharmaceutical Technology is a clinical-stage biotechnology company based in China that specializes in developing targeted therapies for central nervous system (CNS) cancers. Incubated by the venture capital firm Materia Medica Group (Bencao Capital), the company focuses on leveraging the Large Amino Acid Transporter 1 (LAT1) to transport therapeutic agents across the blood-brain barrier. Its lead candidate, QBS72S (also known as NBQ72S), is a small molecule DNA alkylating agent designed to selectively target LAT1-overexpressing tumor cells. The company is currently advancing QBS72S through Phase 2 clinical trials for indications including brain metastases and leptomeningeal disease. Through strategic collaborations, particularly with Quadriga BioSciences, Nantong Materia Medica Bada aims to address significant unmet needs in neuro-oncology.